Swedish American Group focuses on cancer, autoimmune diseases at Life Science Summit

Gene Marcial , Contributor
September 09 2017

Respected and acclaimed as rock stars in the arcane universe of life sciences, global scientists converged in Stockholm in late August this year for the annual Swedish American Life Science Summit (SALSS) meeting, where they unveiled and dissected revolutionary health care platforms. Among them are the use of robotics in surgery, how nanotechnology may make us “forever young,” applications of space technology in life sciences, and the “Moonshot” cancer program initiated by former Vice President Joseph Biden……….


“Part of this year’s conference focus was the current transformation of the HealthTech industry, driven by the ICT and tech players rather than by the traditional medtech companies,” said Barbro C. Ehnbom, chairman and founder of SALSS. Also significant, she added, was the participation of numerous women at this year’s summit, led by the keynote speaker Dr. Bahija Jallal, executive vice president at AsraZeneca and head of Medimmune. “ We are proud and glad that so many prominent women are actually SALSS women, including Dr. Jallal, which made this 2017 summit more exceptional,” said Ms. Ehnbom.

One of the little known companies that attracted a lot of attention at the conference was AVRA Medical Robotics, a development-stage company based in Orlando, Florida, that has a new generation of “semi-autonomous medical robots for image-capture, navigation, and tissue targeting.”

Specifically, these “medical robots” perform computer-assisted surgery, with human medical surgeons operating a remote surgical device via a console. In fact, they are not really robots as we know them: AVRA has developed a “novel and truly robotic single-arms platform for the field of aesthetics, skin and wound care as well as dermato-plastic surgery,” said Barry F. Cohen, AVRA’s CEO and founder. The company’s first design integrates software, image guidance, navigation and targeting systems, to allow autonomous needling of skin, he explained.

“The future of surgery will be determined by success in gaining precision access to anny area of the human body with the smallest incisions and deploying therapies to specific tissues, glands and organs,” asserted Alen York, an AVRA senior executive. Limitations in conventional surgeries, he said, are “demanding more autonomous, intelligent robot systems that go beyond the capability of a human being.”

AVRA’S platform focused on needling technology “represents a key breakthrough in aesthetics, wound care, and autonomous drug delivery platforms, integration of artificial intelligence and augmented reality that will allow,” says York, for a new paradigm in surgical training, planning and treatment.

For complete article please visit forbes.com